The FDA approved Edarbi (azilsartan medoxomil), a new angiotensin receptor blocker, for the treatment of hypertension in adults.
Alexander White, PharmD Candidate
Advertisement
Articles by Alexander White, PharmD Candidate
Advertisement
Latest Updated Articles
- Takeda Pharmaceuticals America, Inc's Edarbi
May 16th 2011
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Factors Associated With GLP-1 RA Nonresponse in T2D—and What Pharmacists Should Screen For
2
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
3
ADA 2026: Optimized Inhaled Insulin Dosing Outperforms Subcutaneous Analogs for Postprandial Glucose in T1D
4
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
5